title: Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers.
abstract: OBJECTIVE
  The aim of the study was to evaluate the prognostic significance of p53 and PTEN in patients with epithelial ovarian cancer who were treated with taxane and platinum-based chemotherapy.
  
  
  METHODS
  Retrospectively collected paraffin blocks from 151 epithelial ovarian cancer patients treated with debulking surgery followed by taxane and platinum chemotherapy were analyzed. Expression of p53 and PTEN was assessed by immunohistochemistry. The staining pattern was correlated with clinicopathological variables.
  
  
  RESULTS
  Overexpression of p53 was found in 80 of the 151 cases (53.0%), and it was related to stage, histology and grade. Reduced expression of PTEN was found in 104 of the 151 cases (68.9%), and it was not related to any clinicopathological factors other than age. In survival analysis, stage (p=0.001), residual tumor (p=0.045), lymph node metastases (p=0.012), and PTEN expression (p=0.009) were significant predictors for disease-free survival (DFS). The median DFS of patients with reduced PTEN expression was 20 months (range, 3-71 months), whereas that of patients with normal PTEN expression was 53 months (range, 2-81 months).
  
  
  CONCLUSIONS
  Reduced PTEN expression is a poor prognostic factor for DFS in patients with epithelial ovarian cancer who were treated with debulking surgery and postoperative taxane and platinum chemotherapy.
authors.affiliation: Department of Obstetrics and Gynecology, Seoul National University Hospital, 28 Yungun-Dong, Chongno-Gu, Seoul 110-744, South Korea. yookyung@snu.ac.kr
authors.forename: Yoo-Kyung
authors.initials: YK
authors.lastname: Lee
authors.forename: Noh-Hyun
authors.initials: NH
authors.lastname: Park
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology* / Q000628:therapy; D051059:PTEN Phosphohydrolase / Q000096:biosynthesis* / Q000235:genetics; D017239:Paclitaxel / Q000008:administration & dosage; D011379:Prognosis; D012189:Retrospective Studies; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis* / Q000235:genetics; D055815:Young Adult
chemical_list: C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D016190:Carboplatin; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human; D017239:Paclitaxel; D002945:Cisplatin